Novo Integrated Sciences, Inc. has received a delisting determination letter from Nasdaq on August 9, 2024, due to non-compliance with the Minimum Bid Price Requirement. The company's common stock failed to maintain the required $1.00 per share bid price over the last 30 consecutive business days. Although Novo Integrated Sciences was given a 180-day period to regain compliance, it was unable to meet the requirement by the deadline of August 7, 2024. The company plans to request a hearing before a Nasdaq Hearing Panel, which will stay the delisting while the company presents its plan to regain compliance. The Panel may grant an extension until February 5, 2025, but there is no guarantee of this extension or that the company will ultimately satisfy Nasdaq's continued listing criteria.

Novo Integrated Sciences, Inc. has received a delisting determination letter from Nasdaq on August 9, 2024, due to non-compliance with the Minimum Bid Price Requirement. The company's common stock failed to maintain the required $1.00 per share bid price over the last 30 consecutive business days. Although Novo Integrated Sciences was given a 180-day period to regain compliance, it was unable to meet the requirement by the deadline of August 7, 2024. The company plans to request a hearing before a Nasdaq Hearing Panel, which will stay the delisting while the company presents its plan to regain compliance. The Panel may grant an extension until February 5, 2025, but there is no guarantee of this extension or that the company will ultimately satisfy Nasdaq's continued listing criteria.